Atlas Trials

A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Clinical trial NCT05969171 · RECRUITING

Trial details

NCT number
NCT05969171
Sponsor
Fudan University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer Metastatic
Start date
2023-12-05
Primary completion
2026-12-31
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.